Potential IPF add-on therapy NXP002 reduces fibrosis markers, early tests show | Nuformix plans to test NXP002 on lung tissue from patients, healthy voluntee...
Treatment with Nuformix's experimental therapy NXP002 reduced markers of fibrosis in a laboratory model of idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
